Journal ArticleOPEN ACCESS

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

  • Kalra S
  • Sahay R
  • Baruah M
Cardiology and Therapy (2016) 5(2) 169-169
DOI: 10.1007/s40119-016-0070-6
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of drugs that have been extensively investigated for the treatment of hyperglycemia in type 2 diabetes mellitus (T2DM). These drugs reduce hyperglycemia by blocking renal glucose reabsorption, thereby promoting increased renal glucose excretion. Beyond glycemic control, these drugs have other beneficial effects on cardiovascular (CV) risk factors. The present review discusses the potential role of SGLT2 inhibitors in treating CV complications (acute and chronic) associated with T2DM. Funding: AstraZeneca Pharma India Ltd.

Cite

CITATION STYLE

APA

Kalra, S., Sahay, R., & Baruah, M. P. (2016). Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review. Cardiology and Therapy, 5(2), 169–169. https://doi.org/10.1007/s40119-016-0070-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free